{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:44:26Z","timestamp":1793054666145,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1007\/s00415-010-5728-8","type":"journal-article","created":{"date-parts":[[2010,11,15]],"date-time":"2010-11-15T20:09:33Z","timestamp":1289851773000},"page":"253-261","source":"Crossref","is-referenced-by-count":212,"title":["Pharmacokinetics of levodopa"],"prefix":"10.1007","volume":"257","author":[{"given":"Manuela","family":"Contin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,11,16]]},"reference":[{"key":"5728_CR1","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/00002826-199210000-00004","volume":"15","author":"R Astarloa","year":"1992","unstructured":"Astarloa R, Mena MA, Sanchez V, de la Vega L, de Yebenes JG (1992) Clinical pharmacokinetic effects of a diet rich of insoluble fiber on Parkinson disease. Clin Neuropharmacol 15:375\u2013380","journal-title":"Clin Neuropharmacol"},{"key":"5728_CR2","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/00002826-198712000-00004","volume":"10","author":"A Baruzzi","year":"1987","unstructured":"Baruzzi A, Contin M, Riva R, Procaccianti G, Albani F, Tonello C, Zoni E, Martinelli P (1987) Influence of meal ingestion time on pharmacokinetics of orally administered levodopa in Parkinsonian patients. Clin Neuropharmacol 10:527\u2013537","journal-title":"Clin Neuropharmacol"},{"key":"5728_CR3","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1212\/WNL.42.10.2042","volume":"2","author":"JH Carter","year":"1992","unstructured":"Carter JH, Nutt JG, Woodward WR (1992) The effect of exercise on levodopa absorption. Neurology 2:2042\u20132045","journal-title":"Neurology"},{"key":"5728_CR4","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/00002826-198906000-00001","volume":"12","author":"JM Cedarbaum","year":"1989","unstructured":"Cedarbaum JM (1989) The promise and limitations of controlled-release oral levodopa administration. Clin Neuropharmacol 12:147\u2013166","journal-title":"Clin Neuropharmacol"},{"key":"5728_CR5","unstructured":"Committee on Dietary Allowances Food and Nutrition Board (ed) (1989) Recommended dietary allowances. National Academy Press, Washington, DC"},{"key":"5728_CR6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00002826-199002000-00002","volume":"13","author":"M Contin","year":"1990","unstructured":"Contin M, Riva R, Martinelli P, Procaccianti G, Cortelli P, Avoni P, Baruzzi A (1990) Response to a standard oral levodopa test in Parkinsonian patients with and without motor fluctuations. Clin Neuropharmacol 13:19\u201328","journal-title":"Clin Neuropharmacol"},{"key":"5728_CR7","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/00002826-199104000-00004","volume":"14","author":"M Contin","year":"1991","unstructured":"Contin M, Riva R, Martinelli P, Procaccianti G, Albani F, Baruzzi A (1991) Combined levodopa-anticholinergic therapy in the treatment of Parkinson\u2019s disease: effect on levodopa bioavailability. Clin Neuropharmacol 14:148\u2013155","journal-title":"Clin Neuropharmacol"},{"key":"5728_CR8","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/BF00626370","volume":"41","author":"M Contin","year":"1991","unstructured":"Contin M, Riva R, Martinelli P, Albani F, Baruzzi A (1991) Effect of age on the pharmacokinetics of oral levodopa in patients with Parkinson\u2019s disease. Eur J Clin Pharmacol 41:463\u2013466","journal-title":"Eur J Clin Pharmacol"},{"key":"5728_CR9","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/mds.870070310","volume":"7","author":"M Contin","year":"1992","unstructured":"Contin M, Riva R, Martinelli P, Baruzzi A (1992) Kinetic\u2013dynamic relationship of oral levodopa: possible biphasic response after sequential doses in Parkinson\u2019s disease. Mov Disord 7:244\u2013248","journal-title":"Mov Disord"},{"key":"5728_CR10","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1212\/WNL.43.2.367","volume":"43","author":"M Contin","year":"1993","unstructured":"Contin M, Riva R, Martinelli P, Cortelli P, Albani F, Baruzzi A (1993) Pharmacodynamic modeling of oral levodopa: clinical application in Parkinson\u2019s disease. Neurology 43:367\u2013371","journal-title":"Neurology"},{"key":"5728_CR11","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1212\/WNL.44.7.1287","volume":"44","author":"M Contin","year":"1994","unstructured":"Contin M, Riva R, Martinelli P, Cortelli P, Albani F, Baruzzi A (1994) Longitudinal monitoring of the levodopa concentration\u2013effect relationship in Parkinson\u2019s disease. Neurology 44:1287\u20131292","journal-title":"Neurology"},{"key":"5728_CR12","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1212\/WNL.46.4.1055","volume":"46","author":"M Contin","year":"1996","unstructured":"Contin M, Riva R, Martinelli P, Triggs EJ, Albani F, Baruzzi A (1996) The rate of motor response to oral levodopa and the clinical progression of Parkinson\u2019s disease. Neurology 46:1055\u20131058","journal-title":"Neurology"},{"key":"5728_CR13","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2165\/00003088-199630060-00004","volume":"30","author":"M Contin","year":"1996","unstructured":"Contin M, Riva R, Albani F, Baruzzi A (1996) Pharmacokinetic optimisation in the treatment of Parkinson\u2019s disease. Clin Pharmacokinet 30:463\u2013481","journal-title":"Clin Pharmacokinet"},{"key":"5728_CR14","first-page":"351","volume":"22","author":"M Contin","year":"1999","unstructured":"Contin M, Riva R, Martinelli P, Cortelli P, Albani F, Baruzzi A (1999) Concentration\u2013effect relationship of levodopa-benserazide dispersible formulation versus standard form in the treatment of complicated motor response fluctuations in Parkinson\u2019s disease. Clin Neuropharmacol 22:351\u2013355","journal-title":"Clin Neuropharmacol"},{"key":"5728_CR15","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/00007691-200112000-00005","volume":"23","author":"M Contin","year":"2001","unstructured":"Contin M, Riva R, Martinelli P, Albani F, Avoni A, Baruzzi A (2001) Levodopa therapy monitoring in patients with Parkinson disease: a kinetic\u2013dynamic approach. Ther Drug Monit 23:621\u2013629","journal-title":"Ther Drug Monit"},{"key":"5728_CR16","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/WNF.0b013e31815c39aa","volume":"31","author":"M Contin","year":"2008","unstructured":"Contin M, Martinelli P, Scaglione C, Avoni P, Albani F, Riva R, Baruzzi A (2008) The effect of entacapone on levodopa rate of absorption and latency to motor response in patients with Parkinson disease. Clin Neuropharmacol 31:267\u2013271","journal-title":"Clin Neuropharmacol"},{"key":"5728_CR17","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1212\/01.wnl.0000233916.57415.9d","volume":"12","author":"D Deleu","year":"2006","unstructured":"Deleu D, Jacob P, Chand P, Sarre S, Colwell A (2006) Effects of caffeine on levodopa pharmacokinetics and pharmacodynamics in Parkinson disease. Neurology 12:897\u2013898","journal-title":"Neurology"},{"key":"5728_CR18","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1365-2125.1995.tb05781.x","volume":"40","author":"J Dingemanse","year":"1995","unstructured":"Dingemanse J, Jorga K, Zurcher G, Schmitt M, Sedek G, Da Prada M, Van Brummelen P (1995) Pharmacokinetic\u2013pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. Br J Clin Pharmacol 40:253\u2013262","journal-title":"Br J Clin Pharmacol"},{"key":"5728_CR19","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/ana.410210409","volume":"21","author":"G Fabbrini","year":"1987","unstructured":"Fabbrini G, Juncos JL, Mouradian MM, Serrati C, Chase TN (1987) Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson\u2019s disease. Ann Neurol 21:370\u2013376","journal-title":"Ann Neurol"},{"key":"5728_CR20","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/ana.410240303","volume":"24","author":"G Fabbrini","year":"1988","unstructured":"Fabbrini G, Mouradian MM, Juncos JL, Schlegel J, Mohr E, Chase TN (1988) Motor fluctuations in Parkinson\u2019s disease: central pathophysiological mechanisms, part I. Ann Neurol 24:366\u2013371","journal-title":"Ann Neurol"},{"key":"5728_CR21","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1212\/WNL.37.6.940","volume":"37","author":"ST Gancher","year":"1987","unstructured":"Gancher ST, Nutt JG, Woodward WR (1987) Peripheral pharmacokinetics of levodopa in untreated, stable and fluctuating Parkinsonian patients. Neurology 37:940\u2013944","journal-title":"Neurology"},{"key":"5728_CR22","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0031-6997(25)06681-5","volume":"27","author":"HC Guldberg","year":"1975","unstructured":"Guldberg HC, Marsden CA (1975) Catechol-O-methyl transferase: pharmacological aspects and physiological role. Pharmacol Rev 27:135\u2013206","journal-title":"Pharmacol Rev"},{"key":"5728_CR23","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/ana.410310611","volume":"31","author":"M Guttman","year":"1992","unstructured":"Guttman M, Leger G, Cedarbaum JM, Reches A, Woodward W, Evans A, Diksic M, Gjedde A (1992) 3-O-methyldopa administration does not alter fluorodopa transport into the brain. Ann Neurol 31:638\u2013643","journal-title":"Ann Neurol"},{"key":"5728_CR24","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2165\/00003088-199529040-00004","volume":"29","author":"S Harder","year":"1995","unstructured":"Harder S, Baas H, Rietbrock S (1995) Concentration\u2013effect relationship of levodopa in patients with Parkinson\u2019s disease. Clin Pharmacokinet 29:243\u2013256","journal-title":"Clin Pharmacokinet"},{"key":"5728_CR25","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2125.1995.tb04407.x","volume":"39","author":"S Harder","year":"1995","unstructured":"Harder S, Baas H, Bergemann N, Demisch L, Rietbrock S (1995) Concentration\u2013effect relationship of levodopa in patients with Parkinson\u2019s disease after oral administration of an immediate release and a controlled release formulation. Br J Clin Pharmacol 39:39\u201344","journal-title":"Br J Clin Pharmacol"},{"key":"5728_CR26","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/archneur.1987.00520220009006","volume":"44","author":"JL Juncos","year":"1987","unstructured":"Juncos JL, Fabbrini G, Mouradian MM, Serrati C, Chase TN (1987) Dietary influences on the antiparkinsonian response to levodopa. Arch Neurol 44:1003\u20131005","journal-title":"Arch Neurol"},{"key":"5728_CR27","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.2165\/00003495-200059060-00004","volume":"59","author":"S Kaakkola","year":"2000","unstructured":"Kaakkola S (2000) Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson\u2019s disease. Drugs 59:1233\u20131250","journal-title":"Drugs"},{"key":"5728_CR28","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJM198804073181402","volume":"318","author":"SJ Kish","year":"1988","unstructured":"Kish SJ, Shannak K, Hornykiewicz O (1988) Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson\u2019s disease: pathophysiologic and clinical implications. N Engl J Med 318:876\u2013881","journal-title":"N Engl J Med"},{"key":"5728_CR29","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1212\/WNL.58.9.1418","volume":"58","author":"K Kompoliti","year":"2002","unstructured":"Kompoliti K, Adler CH, Raman MS, Pincus JH, Leibowitz MT, Ferry JJ, Blasucci L, Caviness JN, Leurgans S, Chase WM, Yones LC, Tan E, Carvey P, Goetz CG (2002) Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics. Neurology 58:1418\u20131422","journal-title":"Neurology"},{"key":"5728_CR30","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/ana.410230611","volume":"23","author":"R Kurlan","year":"1988","unstructured":"Kurlan R, Nutt JG, Woodward WR, Rothfield K, Lichter D, Miller C, Carter JH, Shoulson I (1988) Duodenal and gastric delivery of levodopa in Parkinsonism. Ann Neurol 23:589\u2013595","journal-title":"Ann Neurol"},{"key":"5728_CR31","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/ana.410200212","volume":"20","author":"KL Leenders","year":"1986","unstructured":"Leenders KL, Poewe WH, Palmer AJ, Brenton DP, Frackowiak RS (1986) Inhibition of l-(18F) fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography. Ann Neurol 20:258\u2013262","journal-title":"Ann Neurol"},{"key":"5728_CR32","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s10072-003-0125-z","volume":"24","author":"P Martinelli","year":"2003","unstructured":"Martinelli P, Contin M, Scaglione C, Riva R, Albani F, Baruzzi A (2003) Levodopa pharmacokinetics and dyskinesias: are there sex-related differences? Neurol Sci 24:192\u2013193","journal-title":"Neurol Sci"},{"key":"5728_CR33","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1212\/WNL.25.11.1029","volume":"25","author":"JP Morgan","year":"1975","unstructured":"Morgan JP, Rivera-Calimlim L, Messiha F, Sundaresan PR, Trabert N (1975) Imipramine-mediated interference with levodopa absorption from the gastrointestinal tract in man. Neurology 25:1029\u20131034","journal-title":"Neurology"},{"key":"5728_CR34","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/mds.21346","volume":"15","author":"S Muhlack","year":"2007","unstructured":"Muhlack S, Welnic J, Woitalla D, Muller T (2007) Exercise improves efficacy of levodopa in patients with Parkinson\u2019s disease. Mov Disord 15:427\u2013430","journal-title":"Mov Disord"},{"key":"5728_CR35","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00002826-198403000-00002","volume":"7","author":"JG Nutt","year":"1984","unstructured":"Nutt JG, Fellman JH (1984) Pharmacokinetics of levodopa. Clin Neuropharmacol 7:35\u201349","journal-title":"Clin Neuropharmacol"},{"key":"5728_CR36","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1056\/NEJM198402233100802","volume":"310","author":"JG Nutt","year":"1984","unstructured":"Nutt JG, Woodward WR, Hammerstad JP, Carter JH, Anderson JL (1984) The \u201con-off\u201d phenomenon in Parkinson\u2019s disease. Relation to levodopa absorption and transport. N Engl J Med 310:483\u2013488","journal-title":"N Engl J Med"},{"key":"5728_CR37","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1212\/WNL.36.6.739","volume":"36","author":"JG Nutt","year":"1986","unstructured":"Nutt JG, Woodward WR (1986) Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients. Neurology 36:739\u2013744","journal-title":"Neurology"},{"key":"5728_CR38","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/ana.410220415","volume":"22","author":"JG Nutt","year":"1987","unstructured":"Nutt JG (1987) On\u2013off phenomenon: relation to levodopa pharmacokinetics and pharmacodynamics. Ann Neurol 22:535\u2013540","journal-title":"Ann Neurol"},{"key":"5728_CR39","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/ana.410210610","volume":"21","author":"JG Nutt","year":"1987","unstructured":"Nutt JG, Woodward WR, Gancher ST, Merrick D (1987) 3-O-methyldopa and the response to levodopa in Parkinson\u2019s disease. Ann Neurol 21:584\u2013588","journal-title":"Ann Neurol"},{"key":"5728_CR40","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1212\/WNL.38.10.1553","volume":"38","author":"JG Nutt","year":"1988","unstructured":"Nutt JG, Gancher ST, Woodward WR (1988) Does an inhibitory action of levodopa contribute to motor fluctuations? Neurology 38:1553\u20131557","journal-title":"Neurology"},{"key":"5728_CR41","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1212\/WNL.40.2.340","volume":"40","author":"JG Nutt","year":"1990","unstructured":"Nutt JG (1990) Levodopa-induced dyskinesia: review, observations, and speculations. Neurology 40:340\u2013345","journal-title":"Neurology"},{"key":"5728_CR42","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/ana.410390504","volume":"39","author":"JG Nutt","year":"1996","unstructured":"Nutt JG, Holford NHG (1996) The response to levodopa in Parkinson\u2019s disease: imposing pharmacological law and order. Ann Neurol 39:561\u2013573","journal-title":"Ann Neurol"},{"key":"5728_CR43","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/ana.10189","volume":"51","author":"JG Nutt","year":"2002","unstructured":"Nutt JG, Carter JH, Lea ES, Sexton GJ (2002) Evolution of the response to levodopa during the first 4\u00a0years of therapy. Ann Neurol 51:686\u2013693","journal-title":"Ann Neurol"},{"key":"5728_CR44","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00003088-200645020-00001","volume":"45","author":"D Nyholm","year":"2006","unstructured":"Nyholm D (2006) Pharmacokinetic optimisation in the treatment of Parkinson \u2018s Disease. An update. Clin Pharmacokinet 45:109\u2013136","journal-title":"Clin Pharmacokinet"},{"key":"5728_CR45","first-page":"15","volume":"9","author":"GHM Paalzow","year":"1986","unstructured":"Paalzow GHM, Paalzow LK (1986) l-dopa: how it may exacerbate parkinsonian symptoms. TIPS 9:15\u201319","journal-title":"TIPS"},{"key":"5728_CR46","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1212\/01.wnl.0000221672.01272.ba","volume":"66","author":"M Pierantozzi","year":"2006","unstructured":"Pierantozzi M, Pietroiusti A, Brusa L, Galati S, Stefani A, Lunardi G, Fedele E, Sancesario G, Bernardi G, Bergamaschi A, Magrini A, Stanzione P, Galante A (2006) Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations. Neurology 66:1824\u20131829","journal-title":"Neurology"},{"key":"5728_CR47","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1212\/WNL.34.9.1131","volume":"34","author":"N Quinn","year":"1984","unstructured":"Quinn N, Parkes D, Marsden CD (1984) Control of on\/off phenomenon by continuous intravenous infusion of levodopa. Neurology 34:1131\u20131136","journal-title":"Neurology"},{"key":"5728_CR48","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/1531-8257(200009)15:5<862::AID-MDS1015>3.0.CO;2-S","volume":"15","author":"I Reuter","year":"2000","unstructured":"Reuter I, Harder S, Engelhardt M, Baas H (2000) The effect of exercise on pharmacokinetics and pharmacodynamics of levodopa. Mov Disord 15:862\u2013868","journal-title":"Mov Disord"},{"key":"5728_CR49","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1136\/bmj.4.5727.93","volume":"4","author":"L Rivera-Calimlim","year":"1970","unstructured":"Rivera-Calimlim L, Dujovne CA, Morgan JP, Lasagna L, Bianchine JR (1970) l-dopa treatment failure: explanation and correction. Br Med J 4:93\u201394","journal-title":"Br Med J"},{"key":"5728_CR50","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/00002826-198802000-00003","volume":"11","author":"JI Sage","year":"1988","unstructured":"Sage JI, Schuh L, Heikkila RE, Duvoisin RC (1988) Continuous duodenal infusions of levodopa: plasma concentrations and motor fluctuations in Parkinson\u2019s disease. Clin Neuropharmacol 11:36\u201344","journal-title":"Clin Neuropharmacol"},{"key":"5728_CR51","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/ana.410360512","volume":"36","author":"FJ Vingerhoets","year":"1994","unstructured":"Vingerhoets FJ, Snow BJ, Lee CS, Schulzer M, Mak E, Calne DB (1994) Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism. Ann Neurol 36:759\u2013764","journal-title":"Ann Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-010-5728-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-010-5728-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-010-5728-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T21:21:11Z","timestamp":1740691271000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-010-5728-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":51,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["5728"],"URL":"https:\/\/doi.org\/10.1007\/s00415-010-5728-8","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}